NCT04720417 2025-07-15Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaThomas Jefferson UniversityPhase 2 Terminated13 enrolled 13 charts
NCT02004028 2024-02-20Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVerastem, Inc.Phase 2 Terminated35 enrolled 15 charts